Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 3/20 | 1.00 |
| ▸ | UCHL1 | P09936 | 1/20 | 1.00 |
| ▸ | USP5 | P45974 | 1/20 | 1.00 |
| ▸ | USP4 | Q13107 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | PAM | P19021 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vialinin B SCHEMBL29711168 | 0.79 | SENP1 (0.63) | SENP1UCHL1USP5USP4PREP | |
| SCHEMBL417740 | 0.77 | SENP1 (0.62) | SENP1UCHL1USP5USP4SMN1; SMN2 | |
| SCHEMBL417739 | 0.74 | CYP19A1 (0.67) | SENP1UCHL1USP5USP4SMN1; SMN2 | |
| SCHEMBL29711334 | 0.73 | SENP1 (0.58) | SENP1UCHL1USP5USP4PREP | |
| SCHEMBL2637879 | 0.70 | ASAH1 (0.68) | SENP1UCHL1USP5USP4SMN1; SMN2 | |
| SCHEMBL6937307 | 0.70 | SMN1; SMN2 (0.67) | SENP1UCHL1USP5USP4SMN1; SMN2 | |
| SCHEMBL57331 | 0.70 | ALDH1A1 (0.85) | SENP1UCHL1USP5USP4FNTA | |
| SCHEMBL8862346 | 0.69 | CYP19A1 (0.56) | SENP1UCHL1USP5USP4SMN1; SMN2 | |
| SCHEMBL31226071 | 0.69 | SENP1 (0.61) | SENP1UCHL1USP5USP4SMN1; SMN2 | |
| SCHEMBL10573912 | 0.69 | MAPK1 (0.61) | SENP1UCHL1USP5USP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030135-A2 | METHODS FOR TREATING AND AMELIORATING ANGINA, MYOCARDIAL INFARCTION, REPERFUSION INJURY, HEART ARRHYTHMIAS AND CONGESTIVE HEART FAILURE (CHF) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-06 | — | — | WO | claimed |
| WO-2025029578-A1 | SUMOYLATION AS A THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES AND INFECTIONS DISORDERS | DUKE UNIVERSITY (US) | 2025-02-06 | — | — | WO | claimed |
| WO-2024249339-A1 | COMBINED RTK AND SUMO INHIBITION FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240358731-A1 | SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA | NORTHEASTERN UNIVERSITY | 2024-10-31 | — | — | US | claimed |
| CN-118526480-A | Application of USP4 inhibitor in preparation of leukemia treatment products | 暨南大学 | 2024-08-23 | — | — | CN | claimed |
| CN-119827767-B | Use of ubiquitin-specific protease USP4 for treating acute lung injury/acute respiratory distress syndrome | 重庆医科大学 | 2025-10-28 | — | — | CN | disclosed |
| CN-119827767-A | Use of ubiquitin-specific protease USP4 for treating acute lung injury/acute respiratory distress syndrome | 重庆医科大学 | 2025-04-15 | — | — | CN | disclosed |
| CN-119827767-A | Use of ubiquitin-specific protease USP4 for treating acute lung injury/acute respiratory distress syndrome | 重庆医科大学 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025030135-A2 | METHODS FOR TREATING AND AMELIORATING ANGINA, MYOCARDIAL INFARCTION, REPERFUSION INJURY, HEART ARRHYTHMIAS AND CONGESTIVE HEART FAILURE (CHF) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025029578-A1 | SUMOYLATION AS A THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES AND INFECTIONS DISORDERS | DUKE UNIVERSITY (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-222379009-U | Detection device and intelligent terminal | 上海传英信息技术有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119299561-A | Control method, intelligent terminal and storage medium | 深圳传音控股股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-219417963-U | Multicolor electric control color-changing device, shell assembly and intelligent terminal | 深圳传音控股股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-108966250-B | Weak signal communication method, mobile terminal and computer readable storage medium | 山东沃伦通信技术有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116185549-A | Processing method, intelligent terminal and storage medium | 上海传英信息技术有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116069887-A | Information processing method, intelligent terminal and storage medium | 上海传英信息技术有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115993926-A | Interaction method, intelligent terminal and storage medium | 上海传英信息技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | disclosed |
| CN-110248932-B | Pyrimidine tricycloalkenone derivatives for ROR γ inhibition and other uses | 里亚塔医药公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-114072000-A | Molecules having certain pesticidal effects and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358731-A1 | SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA | SUMO1, SUMO2, SUMO3 | SENP1 10/4885UCHL1 930/4885USP5 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.